Company Filing History:
Years Active: 2025
Title: Fabian Brunk: Innovator in Antigen Binding Proteins
Introduction
Fabian Brunk is a notable inventor based in Tuebingen, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of antigen binding proteins. His work focuses on innovative solutions that have the potential to impact medical applications.
Latest Patents
Fabian Brunk holds a patent for "Antigen binding proteins specifically binding CT45." This invention provides an antigen binding protein that specifically binds to a CT45 antigenic peptide in a complex with a major histocompatibility complex (MHC) protein. The CT45 antigenic peptide comprises the amino acid sequence of SEQ ID NO: 138 (KIFEMLEGV). The antigen binding protein includes a first polypeptide with a variable domain comprising complementarity determining regions CDRa1, CDRa2, and CDRa3, as well as a second polypeptide with a variable domain comprising CDRb1, CDRb2, and CDRb3. Additionally, the invention encompasses nucleic acids encoding these proteins, vectors containing the nucleic acids, recombinant cells expressing the proteins, and pharmaceutical compositions that utilize them. The patent also outlines the use of these proteins in medicine and methods for their production.
Career Highlights
Fabian Brunk is associated with Emmatics Biotechmologie GmbH, where he continues to advance his research and development efforts. His work has garnered attention for its potential applications in therapeutic settings, particularly in the realm of immunology.
Collaborations
Fabian collaborates with talented individuals such as Sara Yousef and Andreas Moritz, who contribute to the innovative environment at Emmatics Biotechmologie GmbH. Their combined expertise fosters a dynamic approach to research and development in biotechnology.
Conclusion
Fabian Brunk's contributions to the field of antigen binding proteins exemplify the innovative spirit of modern biotechnology. His patent and ongoing work hold promise for advancements in medical applications, showcasing the importance of collaboration and research in driving innovation forward.